Design of ODYSSEY-HCM: a phase 3 randomized placebo-controlled study to assess the efficacy and safety of mavacamten in patients with nonobstructive hypertrophic cardiomyopathy

Back

HFA Premium Access

Design of ODYSSEY-HCM: a phase 3 randomized placebo-controlled study to assess the efficacy and safety of mavacamten in patients with nonobstructive hypertrophic cardiomyopathy

Session: Myocardial disease - clinical 9

Topic: Hypertrophic Cardiomyopathy

Speaker: Professor I. Olivotto (Florence, IT)

Event: Heart Failure 2024

Congress Presentation

About the speaker

Professor Iacopo Olivotto

University of Florence, Florence (Italy)

31 presentations

12 followers

6 more presentations in this session

Are sodium-glucose co-transporter 2 inhibitors safe in hypertrophic cardiomyopathy?

Speaker: Doctor V. Biletska (Kharkiv, UA)

Genetic testing in hypertrophic cardiomyopathy: for all or just selected patients?

Speaker: Doctor A. Fonseca Vazao (Leiria, PT)

Hypertrophic cardiomyopathy phenotype and the importance of systemic inflammation

Speaker: Doctor I. Miranda (Amadora, PT)

Could we use cardiopulmonary exercise test to distinguish hypertrophic cardiomyopathy from Fabry disease? New insights from Italy

Speaker: Doctor F. Re (Roma, IT)

Is the mortality of chronic chagas cardiomyopathy higher than cardiomyopathy due to other etiologies? A systematic review and meta-analysis

Speaker: Doctor L. Echeverria (Floridablanca, CO)

Access the full session

Myocardial disease - clinical 9

Speakers: Professor I. Olivotto, Doctor V. Biletska, Doctor A. Fonseca Vazao, Doctor I. Miranda, Doctor F. Re...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources